"Accelerated phase" chronic lymphocytic leukemia: Still an intermediate risk disease in the era of targeted therapies.
Lapierre L, Syrykh C, Largeaud L, Cabarrou B, Filleron T, Oberic L, Kanoun S, Coster L, Laurent C, Branco B, Gadaud N, Récher C, Brechemier D, Balardy L, Vergez F, Ysebaert L, Gauthier M.
Lapierre L, et al. Among authors: syrykh c.
Hematol Oncol. 2022 Oct;40(4):805-808. doi: 10.1002/hon.2985. Epub 2022 Mar 8.
Hematol Oncol. 2022.
PMID: 35246868
No abstract available.